• Pharmaceutical R&D tax incentives

    Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.

  • Megatrends - Health reimagined

    Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.

  • Firepower and growth gap report 2015

    Biopharma M&A reached record levels in 2014, with firms seeking focus, scale and growth. Read more about last year’s deal-making landscape in our 2015 outlook.

  • The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • Navigating the payer landscape in pharma

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • 10 things to know about the 2013 IPO class

    Read our latest blog post, where Glen Giovannetti and colleagues tell the story of the 2013 US biotech IPO class in a 10-chart infographic.

  • Insights from 30 years of biotech IPOs

    In our latest blog post, Global Life Sciences Leader Glen Giovannetti shares his thoughts on past IPO cycles and the outlook for 2014.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Network brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:

  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

    We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

    We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

    So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

    Take a closer look:

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

    Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

    Take a closer look:

  • Media

Contact us

Dmitry Khalilov
 +7 495 755 9757

Dmitry Khalilov
Partner, Tax, Life Sciences Leader, Russia & CIS

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY-Applying IFRS 10 and IFRS 11

Applying IFRS 10 and IFRS 11

How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.


EY - Biopharma in an era of elusive growth

Biopharma in an era of elusive growth

Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.